The use of soluble forms of checkpoints, such as sPD-1, sPD-L1, sCD200, and sCD200R, may be a promising, non-invasive tool for assessing disease activity and differentiating between types of glomerulopathy. This evidence concerns the gene HOXD13 and lipoprotein glomerulopathy.